Futura Medical PLC has appointed Stifel Nicolaus Europe Limited as joint corporate broker, effective immediately. The company, known for its development and global commercialization of innovative sexual health products, including the lead product Eroxon, will continue to work with Liberum as its Nominated Adviser and Joint Corporate Broker. Eroxon, the company's clinically proven lead product, is a topical gel treatment for Erectile Dysfunction (ED) that can help men achieve an erection in ten minutes. This addresses significant unmet needs in the ED market, as ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.